Search

everythingexperts & clinicslearnresearchcommunity

for

Search:↓

The post and conversation are about a user's positive progress with hair loss using minoxidil and finasteride. No noticeable side effects were reported.

miR-205, a tiny RNA, can stimulate hair growth by softening aging hair follicle stem cells in mice. Future tests aim to see if this can work in humans.

User asks if Kintor, HMI-115, or Olix will release hair loss drugs in 2023. Conversation discusses potential treatments and release dates.

New product Tomorrowlabs HSF targets hair loss through HIF pathway indirectly by removing scalp iron. Minoxidil and Stemoxydine also relate to HIF pathway.

Phase II for TDM-105795 for Androgenic Alopecia is set to begin in April 2023. The study aims to evaluate the efficacy and safety of TDM-105795 in male subjects.

The user tried Minoxidil without success, and Finasteride worked but caused sexual side effects even at a very low dose. They are seeking alternative treatments for hair loss as they cannot tolerate anti-androgens and are also in therapy for mental health.

The conversation is about the safety and effects of using pyrilutamide for hair loss. One person reported severe negative effects, another experienced minor side effects without much benefit for hair, and a third found the anecdote helpful in making a decision.

A new Latanoprost-based formula used by Hollywood celebrities to treat hair loss, with the formula containing minoxidil, tretinoin, melatonin, azelaic acid, zinc thymulin, vitamin B6, sandalore and methyl vanillate. It also mentions the potential of offering a combined sublingual minoxidil/oral dutasteride option in the future.

Kintor's GT20029, a treatment for hair loss, has completed Phase 1 successfully, showing promise as an androgen receptor degrader that could potentially regrow hair. It is considered more effective than Pyrilutamide, with infrequent dosing and minimal systemic absorption.

The results of using Pyrilutamide, a hair loss treatment available on the gray market, and other treatments such as Minoxidil, Finasteride and RU58841.

Pyrilutamide, a potential hair loss treatment that is currently in development and may be available soon; an androgen receptor degrader which is also being developed as a potential treatment for hair loss; and the comparison between Pyrilutamide, finasteride, minoxidil, and RU58841.

A user who is using Pyrilutamide, Finasteride, and a homemade topical solution to treat their hair loss. Replies mentioned the potential of Pyrilutamide being a "cure" for hair loss and a reminder that results may not be credited solely to it.

The reasoning for GSK's approval of dutasteride for hair loss in Japan and South Korea but not the US, with alternatives such as finasteride, minoxidil and RU58841 mentioned.

TWIST-1 gene's role in hair loss and potential as a treatment target. Inhibiting TWIST-1 may prolong hair growth and reduce hair follicle sensitivity to DHT.

User on fin, minox, and ketoconazole seeks to add another topical anti-androgen. Hierarchy of effectiveness: 1. RU55841, 2. Fluridil - Eucapil, 3. CB-03-01 - Breezula, 4. Ketoconazole; alfatradiol suggested as addition.

Hair cloning and injection of dermal papilla cells are discussed, with skepticism about their availability by 2023. Users mention Minoxidil, finasteride, and hair transplants as current treatments.

A user shared their hair loss treatment which includes a custom solution with multiple ingredients, caffeine liquid, and saw palmetto, and mentioned shedding after 40 days of use. Some replies discuss the effectiveness and cost of the treatment, while others debate the usefulness of topical dutasteride.

A user with aggressive male pattern baldness found that topical melatonin significantly reduced their hair shedding to 1 or 2 hairs per day and noticed some thickening of side hair. They tried many treatments like finasteride and minoxidil with little success, but topical melatonin showed immediate results in reducing hair loss.

User experienced reduced hair loss with 15mg RU in Serioxyl but had concerning chest pain. Others suggested consulting a doctor or lowering the dose.

A user shared their experience with hair loss treatments, including RU58841, ketoconazole shampoo, caffeine shampoo, and topical finasteride. They found RU58841 effective for diffuse thinning but experienced severe hair loss after stopping it; topical finasteride worked well for a receding hairline but caused side effects. They also use a charcoal shampoo and practice scalp massages.

The conversation discusses arranging an interview with the developers of RU58841 to clarify its safety and reasons for halted research, with some users expressing concerns about potential risks and others citing financial reasons for the discontinuation of studies. Specific treatments mentioned include RU58841, minoxidil, and finasteride.

Cassiopea claimed that their hair loss treatment, Clascoterone, shows comparable results to finasteride after six months of use. Some users believe Clascoterone could be an additional treatment option for those who do not respond to finasteride.

Minoxidil may suppress androgen activity in hair follicles, potentially aiding in hair growth and prostate cancer treatment. Users discuss the effectiveness of minoxidil and finasteride for hair maintenance and regrowth, with some preferring topical applications over oral due to safety concerns.

The conversation discusses using NAC (N-Acetyl Cysteine) alongside minoxidil and finasteride for hair loss, with some users noting potential hairline improvement and increased energy. The original poster reduced their finasteride dosage due to mental decline and anxiety, and while NAC's effects on hair are anecdotal, it is considered low-risk with other health benefits.

HairClone is developing cell replacement treatments to rejuvenate and generate hair follicles, and has launched a crowdfunding campaign. A user expressed skepticism about the need for crowdfunding.

The conversation discusses Fevipiprant, an asthma drug that may block CRTH2 and potentially stop male pattern baldness (MPB) without inhibiting DHT. It also mentions the use of finasteride and dutasteride for hair loss.

DHT is not the only cause of male pattern hair loss; genetic sensitivity, inflammation, and fibrosis also contribute. GHK-Cu, a copper peptide, is being explored as an alternative treatment to finasteride and minoxidil, showing potential in improving follicle health.

The user is experiencing significant hair shedding after three months on oral Dutasteride, Minoxidil, and Vitamin D3, but remains hopeful as shedding can indicate treatment effectiveness. They consider adding topical Minoxidil and dermal needling, while others advise patience.

The user discovered their previous hair loss medication was counterfeit and switched to Propecia, which significantly lowered their DHT levels. They plan to continue using Propecia and add oral Minoxidil to their routine for better results.

Finasteride and Propecia are essentially the same, but some people may respond differently due to inactive ingredients. If cost is not an issue, Propecia is preferred due to better quality control and consistent results.